UA118094C2 - Заміщені зворотні піримідинові інгібітори bmi-1 - Google Patents
Заміщені зворотні піримідинові інгібітори bmi-1Info
- Publication number
- UA118094C2 UA118094C2 UAA201505533A UAA201505533A UA118094C2 UA 118094 C2 UA118094 C2 UA 118094C2 UA A201505533 A UAA201505533 A UA A201505533A UA A201505533 A UAA201505533 A UA A201505533A UA 118094 C2 UA118094 C2 UA 118094C2
- Authority
- UA
- Ukraine
- Prior art keywords
- bmi
- inhibitors
- substituted reverse
- reverse pyrimidine
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Oncology (AREA)
Abstract
У цьому винаході описані амінозаміщені обернені піримідинові сполуки та їх форми, які інгібують функцію та знижують рівень специфічного до В-клітин білка інсерційного сайта 1 вірусу лейкозу мишей Молоні (Вmі-1), та способи їх застосування для інгібування функції Вmі-1 та зниження рівня Вmі-1 для лікування раку, опосередкованого Вmі-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728907P | 2012-11-21 | 2012-11-21 | |
PCT/US2013/071132 WO2014081906A2 (en) | 2012-11-21 | 2013-11-21 | Substituted reverse pyrimidine bmi-1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
UA118094C2 true UA118094C2 (uk) | 2018-11-26 |
Family
ID=50776672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201505533A UA118094C2 (uk) | 2012-11-21 | 2013-11-21 | Заміщені зворотні піримідинові інгібітори bmi-1 |
Country Status (32)
Country | Link |
---|---|
US (3) | US10428050B2 (uk) |
EP (1) | EP2922828B1 (uk) |
JP (3) | JP6412503B2 (uk) |
KR (4) | KR20220143164A (uk) |
CN (2) | CN111423417B (uk) |
AR (1) | AR093579A1 (uk) |
AU (1) | AU2013348009C1 (uk) |
BR (1) | BR112015011760B1 (uk) |
CA (1) | CA2892045C (uk) |
CL (1) | CL2015001377A1 (uk) |
CR (1) | CR20150294A (uk) |
CU (1) | CU24387B1 (uk) |
DK (1) | DK2922828T3 (uk) |
EA (2) | EA035349B1 (uk) |
EC (1) | ECSP15019948A (uk) |
ES (1) | ES2821529T3 (uk) |
HK (1) | HK1215032A1 (uk) |
IL (2) | IL238871B (uk) |
MA (1) | MA38208B1 (uk) |
MX (2) | MX2015006469A (uk) |
NI (1) | NI201500072A (uk) |
NZ (2) | NZ746607A (uk) |
PE (1) | PE20151413A1 (uk) |
PH (1) | PH12015501130A1 (uk) |
PL (1) | PL2922828T3 (uk) |
PT (1) | PT2922828T (uk) |
SA (1) | SA517381847B1 (uk) |
SG (2) | SG11201503982XA (uk) |
TW (1) | TWI623531B (uk) |
UA (1) | UA118094C2 (uk) |
WO (1) | WO2014081906A2 (uk) |
ZA (1) | ZA201503642B (uk) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA035349B1 (ru) * | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
JP6529492B2 (ja) * | 2013-07-11 | 2019-06-12 | アジオス ファーマシューティカルズ, インコーポレイテッド | 癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物 |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
EA034866B1 (ru) | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
US10874355B2 (en) | 2014-04-24 | 2020-12-29 | Cognoa, Inc. | Methods and apparatus to determine developmental progress with artificial intelligence and user input |
US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
EP3402780A1 (en) * | 2016-01-14 | 2018-11-21 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
AU2018219846A1 (en) * | 2017-02-09 | 2019-09-12 | Cognoa, Inc. | Platform and system for digital personalized medicine |
WO2019028171A1 (en) | 2017-08-01 | 2019-02-07 | Ptc Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
AU2019340402A1 (en) | 2018-08-17 | 2021-03-25 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
CN109988172B (zh) * | 2019-01-10 | 2020-09-29 | 石家庄学院 | 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法 |
EP3911418A1 (en) | 2019-01-15 | 2021-11-24 | PTC Therapeutics, Inc. | Method for treating an acute myeloid leukemia |
CA3131249A1 (en) * | 2019-02-28 | 2020-09-03 | Ptc Therapeutics, Inc. | 5-fluoro-2-(6fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine dor treating a multiple myeloma |
HUE062796T2 (hu) * | 2019-03-11 | 2023-12-28 | Ptc Therapeutics Inc | Megnövelt biológiai hozzáférhetõséggel rendelkezõ vegyületforma és annak készítményei |
MX2021011493A (es) | 2019-03-22 | 2022-01-04 | Cognoa Inc | Métodos y dispositivos de terapia digital personalizados. |
EP3947379A4 (en) * | 2019-03-27 | 2022-12-21 | PTC Therapeutics, Inc. | COMBINATIONS FOR USE IN A METHOD OF TREATMENT OF SARCOMA |
US20220177459A1 (en) * | 2019-04-02 | 2022-06-09 | Hinova Pharmaceuticals Inc. | Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH593266A5 (uk) | 1973-09-20 | 1977-11-30 | Delalande Sa | |
AU688087B2 (en) * | 1994-08-13 | 1998-03-05 | Yuhan Corporation | Novel pyrimidine derivatives and processes for the preparation thereof |
IN188411B (uk) | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
KR100272471B1 (ko) | 1998-11-17 | 2000-11-15 | 김선진 | 신규의 피리미딘 유도체 및 그의 제조방법 |
GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
ATE253915T1 (de) | 1999-06-30 | 2003-11-15 | Merck & Co Inc | Src-kinase hemmende verbindungen |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
JP2003512467A (ja) | 1999-10-27 | 2003-04-02 | ノバルティス アクチエンゲゼルシャフト | チアゾールおよびイミダゾ(4,5−b)ピリジン化合物ならびにそれらの医薬用途 |
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
GB2361236B (en) | 2000-03-29 | 2002-04-24 | Cyclacel Ltd | Pyrimidines useful against proliferative disorders |
WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1330452B1 (en) | 2000-09-20 | 2008-11-26 | Ortho-McNeil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
JP2004515550A (ja) | 2000-12-15 | 2004-05-27 | グラクソ グループ リミテッド | 治療用化合物 |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
ES2316546T3 (es) | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
EP1975620A3 (en) | 2001-03-02 | 2008-12-24 | GPC Biotech AG | Three hybrid assay system |
US7196095B2 (en) | 2001-06-25 | 2007-03-27 | Merck & Co., Inc. | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds |
ES2271283T3 (es) | 2001-07-03 | 2007-04-16 | Vertex Pharmaceuticals Incorporated | Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck. |
WO2003011837A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003075828A2 (en) | 2002-03-11 | 2003-09-18 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
NZ537156A (en) | 2002-05-23 | 2007-06-29 | Cytopia Pty Ltd | Kinase inhibitors |
WO2004002963A1 (ja) | 2002-06-28 | 2004-01-08 | Nippon Shinyaku Co., Ltd. | アミド誘導体及び医薬 |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
WO2004007407A2 (en) * | 2002-07-11 | 2004-01-22 | Fluorous Technologies Incorporated | Fluorous tagging and scavenging reactants and methods of synthesis and use thereof |
US20040110821A1 (en) * | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
JP2006504755A (ja) | 2002-10-15 | 2006-02-09 | スミスクライン ビーチャム コーポレーション | Gsk−3阻害薬としてのピリダジン化合物 |
US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
KR101164541B1 (ko) | 2004-01-12 | 2012-07-10 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 선택적 키나제 저해제 |
EP1713793A4 (en) | 2004-02-04 | 2009-09-02 | Smithkline Beecham Corp | PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS |
CN101676285A (zh) * | 2004-03-30 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 用作jak和其它蛋白激酶抑制剂的氮杂吲哚 |
JP2006045119A (ja) | 2004-08-04 | 2006-02-16 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
KR100917511B1 (ko) | 2005-02-28 | 2009-09-16 | 니뽄 다바코 산교 가부시키가이샤 | Syk 저해 활성을 갖는 신규한 아미노피리딘 화합물 |
EP1858882A1 (en) | 2005-03-10 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
ES2340093T3 (es) | 2006-06-22 | 2010-05-28 | Biovitrum Ab (Publ) | Derivados pirazina y piridina como inhibidores de cinasa mnk. |
EP2074113A1 (en) * | 2006-10-03 | 2009-07-01 | NeuroSearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
CN101516873A (zh) * | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
ZA200902384B (en) | 2006-10-19 | 2010-07-28 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
BRPI0720635A2 (pt) | 2006-12-22 | 2014-01-07 | Novartis Ag | Compostos orgânicos e seus usos |
PE20081636A1 (es) | 2007-01-26 | 2009-01-10 | Smithkline Beecham Corp | Inhibidores de antranilamida para aurora quinasa |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
GB0714573D0 (en) | 2007-07-26 | 2007-09-05 | Imp Innovations Ltd | Marker gene |
EP2203436A1 (en) | 2007-09-17 | 2010-07-07 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
AU2008321046B2 (en) | 2007-11-16 | 2013-10-24 | Incyte Holdings Corporation | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
PT2231636E (pt) | 2007-12-07 | 2012-01-02 | Novartis Ag | Derivados de pirazole e a sua utilização a título de inibidores de quinases dependentes de ciclina |
DE102008005493A1 (de) | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
WO2009131687A2 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EP2306836B1 (en) | 2008-07-01 | 2016-09-07 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
WO2010016005A1 (en) | 2008-08-06 | 2010-02-11 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
EP2331527A1 (en) * | 2008-09-02 | 2011-06-15 | NeuroSearch A/S | Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
WO2010061903A1 (ja) * | 2008-11-27 | 2010-06-03 | 塩野義製薬株式会社 | Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体 |
JPWO2010092962A1 (ja) | 2009-02-12 | 2012-08-16 | アステラス製薬株式会社 | へテロ環誘導体 |
CA2756067A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8536180B2 (en) | 2009-05-27 | 2013-09-17 | Abbvie Inc. | Pyrimidine inhibitors of kinase activity |
TW201102387A (en) | 2009-06-08 | 2011-01-16 | Medicinova Inc | Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity |
NZ619259A (en) * | 2009-06-17 | 2015-07-31 | Vertex Pharma | Inhibitors of influenza viruses replication |
EP2532659A1 (en) | 2009-07-07 | 2012-12-12 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
WO2011008915A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
WO2011008830A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
CN102812022B (zh) | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
WO2012022725A2 (en) * | 2010-08-19 | 2012-02-23 | F. Hoffmann-La Roche Ag | Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs) |
AU2011303978B2 (en) | 2010-09-13 | 2014-07-03 | Novartis Ag | Triazine-oxadiazoles |
WO2012050884A2 (en) * | 2010-09-28 | 2012-04-19 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
WO2012078777A1 (en) | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
AU2012221925B2 (en) | 2011-02-25 | 2016-05-05 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
CA2840883C (en) * | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
EA035349B1 (ru) | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
-
2013
- 2013-11-21 EA EA201890142A patent/EA035349B1/ru not_active IP Right Cessation
- 2013-11-21 EA EA201590992A patent/EA031405B1/ru unknown
- 2013-11-21 WO PCT/US2013/071132 patent/WO2014081906A2/en active Application Filing
- 2013-11-21 AR ARP130104300A patent/AR093579A1/es active IP Right Grant
- 2013-11-21 CN CN202010080540.0A patent/CN111423417B/zh active Active
- 2013-11-21 BR BR112015011760-0A patent/BR112015011760B1/pt active IP Right Grant
- 2013-11-21 DK DK13857326.6T patent/DK2922828T3/da active
- 2013-11-21 US US14/443,911 patent/US10428050B2/en active Active
- 2013-11-21 MA MA38208A patent/MA38208B1/fr unknown
- 2013-11-21 SG SG11201503982XA patent/SG11201503982XA/en unknown
- 2013-11-21 CN CN201380070973.6A patent/CN104918919A/zh active Pending
- 2013-11-21 CA CA2892045A patent/CA2892045C/en active Active
- 2013-11-21 NZ NZ74660713A patent/NZ746607A/en unknown
- 2013-11-21 EP EP13857326.6A patent/EP2922828B1/en active Active
- 2013-11-21 CU CU2015000053A patent/CU24387B1/es unknown
- 2013-11-21 KR KR1020227035587A patent/KR20220143164A/ko not_active IP Right Cessation
- 2013-11-21 KR KR1020157016184A patent/KR102275676B1/ko active IP Right Grant
- 2013-11-21 SG SG10201600149VA patent/SG10201600149VA/en unknown
- 2013-11-21 AU AU2013348009A patent/AU2013348009C1/en active Active
- 2013-11-21 UA UAA201505533A patent/UA118094C2/uk unknown
- 2013-11-21 JP JP2015544124A patent/JP6412503B2/ja active Active
- 2013-11-21 PL PL13857326T patent/PL2922828T3/pl unknown
- 2013-11-21 KR KR1020217020963A patent/KR102356487B1/ko active IP Right Grant
- 2013-11-21 PT PT138573266T patent/PT2922828T/pt unknown
- 2013-11-21 KR KR1020227002513A patent/KR102455889B1/ko active IP Right Grant
- 2013-11-21 NZ NZ70890913A patent/NZ708909A/en unknown
- 2013-11-21 ES ES13857326T patent/ES2821529T3/es active Active
- 2013-11-21 TW TW102142555A patent/TWI623531B/zh active
- 2013-11-21 MX MX2015006469A patent/MX2015006469A/es unknown
- 2013-11-21 PE PE2015000665A patent/PE20151413A1/es unknown
-
2015
- 2015-05-18 IL IL238871A patent/IL238871B/en active IP Right Grant
- 2015-05-20 CL CL2015001377A patent/CL2015001377A1/es unknown
- 2015-05-21 MX MX2021009892A patent/MX2021009892A/es unknown
- 2015-05-21 EC ECIEPI201519948A patent/ECSP15019948A/es unknown
- 2015-05-21 NI NI201500072A patent/NI201500072A/es unknown
- 2015-05-21 PH PH12015501130A patent/PH12015501130A1/en unknown
- 2015-05-21 SA SA517381847A patent/SA517381847B1/ar unknown
- 2015-05-22 ZA ZA2015/03642A patent/ZA201503642B/en unknown
- 2015-06-05 CR CR20150294A patent/CR20150294A/es unknown
-
2016
- 2016-03-16 HK HK16103069.2A patent/HK1215032A1/zh unknown
-
2018
- 2018-09-28 JP JP2018183173A patent/JP6617186B2/ja active Active
-
2019
- 2019-03-10 IL IL265253A patent/IL265253A/en unknown
- 2019-09-26 US US16/583,442 patent/US11180483B2/en active Active
- 2019-11-11 JP JP2019203706A patent/JP6918898B2/ja active Active
-
2021
- 2021-11-10 US US17/523,480 patent/US20220064150A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501130A1 (en) | Substituted reverse pyrimidine bmi-1 inhibitors | |
MX2016002642A (es) | Inhibidores de la bmi-1 de pirimidina sustituida. | |
MX2018001430A (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
NZ718190A (en) | Substituted quinazolines for inhibiting kinase activity | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201692338A1 (ru) | Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы | |
PH12018500409A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
NZ716392A (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
TN2018000020A1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors. | |
PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
IN2014KN02906A (uk) | ||
MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
EA201491013A1 (ru) | Пиразиновые ингибиторы киназы | |
MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
EA201590656A1 (ru) | Азаиндолины | |
PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors | |
PH12018500407A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
EA201990239A1 (ru) | Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы |